Specialty vaccine maker Valneva SE’s (NASDAQ:VALN) biologics license application for its single-shot chikungunya vaccine candidate VLA1553 has received a priority review from the U.S. Food and Drug Administration.
Next, the prescription drug user fee act (PDUFA) date for the review has now been set for the end of August this year.
At present, there are no effective treatments or preventive vaccines for chikungunya on the market and over 75% of the global population currently resides in areas with a risk of chikungunya transmission.
Overall, Wall Street has a consensus price target of $25 on VALN, implying a whopping 97% potential upside in the stock. That’s after a nearly 60% side in the share price over the past 52 weeks.
Read full Disclosure
